Host immunity enhancement

Host immunity enhancement is a broad therapeutic strategy aimed at augmenting the body's natural immune system to effectively identify and eliminate pathogens or malignant cells. Rather than being a single molecular target, it encompasses a wide range of pharmacological approaches, including the activation of innate immune sensors (such as Toll-like receptors), the administration of exogenous cytokines, and the blockade of inhibitory checkpoints (such as PD-1 or CTLA-4) [PMID: 32296490, PMID: 30405206]. This approach is a cornerstone of modern oncology, where it is used to overcome tumor-induced immunosuppression, as well as in the treatment of chronic infections where the host response is insufficient for clearance [PMID: 29339414]. Because it represents a physiological outcome or a clinical objective rather than a specific protein, enzyme, or receptor, it is classified as a descriptive term for a therapeutic effect. Drugs that achieve host immunity enhancement vary significantly in their molecular targets, but they share the common goal of shifting the immune environment toward a pro-inflammatory or effector state [PMID: 30121644].

Other names

ImmunostimulationImmunopotentiationImmune enhancementHost defense augmentationImmunomodulation (positive)

As a broad therapeutic goal, host immunity enhancement is achieved through multiple mechanisms including immune checkpoint inhibition, Toll-like receptor (TLR) agonism, cytokine supplementation, and vaccination to stimulate antigen-specific responses [PMID: 32296490].